2025-12-29 - Analysis Report
Okay, here's a comprehensive report on TransMedics Group Inc. (TMDX), incorporating the data and news provided.

**1. Return Rate Comparison:**

*   **Ticker:** TMDX (TransMedics Group Inc)
*   **Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ care system (OCS) solutions for transplantation.
*   **TMDX Cumulative Return:** 205.68%
*   **S&P 500 (VOO) Cumulative Return:** 78.45%
*   **Divergence:**
    *   Current: 138.1
    *   Relative Divergence: 66.1%

**Analysis of Alpha/Beta:**

The provided table shows a cyclical pattern of risk adjusted metrics.
*   **Alpha:** TMDX consistently generates positive alpha, indicating outperformance relative to its benchmark (S&P 500) after accounting for market risk. The alpha fluctuates but consistently showing positive returns.
*   **Beta:** The beta values are low, close to zero to 0.3, suggesting that the stock's price is less sensitive to market movements, indicating less volatility relative to the market.
*   **CAGR:** Compound Annual Growth Rate has been positive for the most recent reporting periods, indicating the recent high growth.
*   **MDD:** Maximum Drawdown remains high over 80%, suggesting risk from the high volitility of the stock.

**2. Recent Stock Price Fluctuations:**

*   **Current Close:** $124.20
*   **Previous Close:** $126.99
*   **Change:** -$2.20
*   **5-day SMA:** $127.28
*   **20-day SMA:** $131.54
*   **60-day SMA:** $125.80

**Analysis:**

The stock price is currently below its 5-day, 20-day SMA. The negative change indicates a recent downward trend. The 5-day SMA is below the 20-day SMA, reinforcing this short-term bearish signal. The 60-day SMA is currently under the price, indicating that the price might continue its downward trend.

**3. Technical Indicators & Outlook:**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 31.25 (Approaching Oversold)
*   **PPO:** -0.66 (Negative - indicates a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 1.2% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 0.6 (+), suggesting short-term upward momentum.
*   **Expected Return:** 47.6% (Long-term)

**Analysis:**

Despite the recent price drop, the MRI suggests a high investment recommendation. The RSI indicates the stock is approaching oversold conditions, which can signal a potential buying opportunity. However, the negative PPO indicates a prevailing downtrend. Recent (20 days) relative divergence change suggests short-term upward momentum, which contradicts with other bearish signals.

**4. Recent News & Significant Events:**

*   **Positive Ratings:** Wall Street Zen upgraded TransMedics Group's stock rating.
*   **Growth Stock Recognition:**  Yahoo Finance identifies TransMedics as a strong growth stock.
*   **Insider Activity:** Quiver Quantitative highlights opinions on recent insider sales (need to evaluate if sales are positive or negative).
*   **Upside Potential:** Seeking Alpha estimates a significant upside potential by the end of 2028.
*   **Hiring Incentives:** New hires receive stock options and units with long vesting periods, suggesting confidence in the company's long-term performance.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.67)
*   **Target Price (avg/high/low):** 144.73 / 170.00 / 114.00

**Analysis:**

Analyst sentiment is strongly positive with a "Buy" consensus and a substantial average target price significantly above the current price. This suggests analysts believe the stock is undervalued.

**5. Comprehensive Analysis:**

TMDX has significantly outperformed the S&P 500 over the period examined, as evidenced by the high cumulative return and divergence. The stock exhibits relatively low beta, indicating less volatility compared to the overall market, high alpha scores, and positive CAGR for recent reporting periods.

The recent price decline, indicated by the negative change, falling SMAs, and negative PPO, presents a mixed picture. The RSI is approaching oversold territory, which could indicate a potential rebound. The news flow is overwhelmingly positive, with analysts upgrading the stock, highlighting its growth potential, and setting high target prices. The MRI indicating a high investment recommendation.

**Overall Recommendation:**

The positive analyst ratings, news headlines, and strong historical outperformance suggest that TMDX may present a buying opportunity, particularly if the price decline continues. However, investors should be aware of the recent downward trend and potential risks indicated by the negative PPO. The high MDD values suggest risk tolerance for investors.

**Disclaimer:** I am an AI chatbot and cannot provide financial advice. This analysis is for informational purposes only, and you should consult with a qualified financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.